CHESTER, NY / ACCESSWIRE / March 27, 2017 / Repro Med Systems, Inc. dba RMS Medical Products (REPR) ("RMS" or the "Company") announced today the successful launch of a new product. The F3CP Variable Flow Rate Controller has been combined with the RMS FREEDOM60® and RMS HIgH-Flo™ Subcutaneous Safety Needle Sets for use in a clinical trial in Sweden to administer HYQVIA, a drug used to treat Primary Immunodeficiency (PID). The F3CP Variable Rate Flow Controller was designed specifically for this drug viscosity, resulting in the RMS FREEDOM60® System being the easiest and safest delivery system for home use.

Eric Bauer, COO of RMS said, "Due to the complexity of electronic systems and flow rate protocol, this is the first time that patients were able to receive this medication at home, and reported an incredible 95% patient satisfaction. There are thousands of patients around the world who have been diagnosed with immune deficiencies. They now have a safe, effective and lower cost method for home infusion of this life changing medication. The RMS system by design has limited constant pressure which prevents many of the adverse side effects caused by other variable pressure infusion systems."

The F3CP Variable Flow Rate Controller has received an official CE mark and registration in Canada. It is now commercially available in Canada and Europe and is currently being used by patients throughout Sweden and Germany. U.S. availability is awaiting FDA clearance which is expected in the near future.

RMS Medical Products is the leading manufacturer of medical products used for home infusions and suctioning. The Infusion product portfolio currently includes the FREEDOM60® and our latest FreedomEdge® Syringe Infusion Pumps, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo™ Subcutaneous Safety Needle Sets. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company's RES-Q-VAC® line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers. The Company's website may be visited at www.rmsmedicalproducts.com.

This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the company's reports and registration statements filed with the Securities and Exchange Commission.

For More Information Please Call:

Princeton Research, Inc
Mike King 702.650.3000

SOURCE: Repro Med Systems, Inc.